-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since December 2018, the state organized the “4+7” 11 cities to carry out the centralized procurement of drugs in 11 cities.
China has organized five batches of centralized procurement of drugs.
From the results, a large number of drugs have reduced prices through centralized procurement.
, Especially in the fifth batch of national centralized procurement, the number of varieties and the average decline have reached new highs
.
It is reported that the fifth batch of national procurement of medicines has a total of 61 products selected, with an average decrease of 56%; the varieties involve common diseases such as hypertension, diabetes, coronary heart disease, digestive tract diseases, and drugs for chronic diseases, as well as drugs for major diseases such as lung cancer and pancreatic cancer.
.
In the recent past, many provinces have begun to issue documents clarifying that the fifth batch of national procurement will be implemented
.
In this regard, the industry believes that at the same time that the tide of drug price cuts hits, a new competitive landscape in the pharmaceutical market will also be coming
.
Specifically, starting from October 9th, the results of the fifth batch of national-organized centralized drug procurement will be implemented in Guangdong
.
It is reported that the national centralized procurement set a record high, with a larger scale, more varieties, and a higher proportion of injection varieties
.
For example, the varieties cover common diseases such as high blood pressure, coronary heart disease, diabetes, anti-allergic, anti-infection, gastrointestinal diseases, and chronic disease drugs, as well as drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer
.
It is worth mentioning that there are 16 varieties in this collection that have a decline of more than 90%.
Among them, Jiangsu Hausen's gemcitabine hydrochloride for injection (1g) and other 6 companies have a decline of more than 97%
.
Taking bendamustine hydrochloride (100mg) for injection in the Netherlands as an example of an anti-tumor drug, the cost of each injection has been reduced from 6000 yuan to 786 yuan after the price reduction.
Based on 8 cycles, the patient can save about 160,000 yuan
.
In addition to the sharp price cuts of the selected products this time, Guangdong also linked the prices of non-selected drugs with the same generic names.
For example, more than 10 drugs such as fasudil hydrochloride injection have also dropped significantly, with an average drop of 70%, and the highest drop.
Is 98%
.
Of course, in addition to a large number of drugs in Guangdong Province, which will usher in price cuts, starting from October 10th, Hubei Province will also implement the fifth batch of national drug collection and Chongqing, Hubei, Qiong, Dianqing, Ning, Xinjiang Corps common drug alliance with volume procurement (Hubei ) Results
.
It is understood that the average price of a total of 80 selected drugs will be reduced by more than 50%
.
In fact, in addition to the above-mentioned provinces, Hubei, Henan, Liaoning, Xinjiang, Shanghai, Tibet and other provinces have successively clarified the time for the implementation of the fifth batch of national procurement since August
.
On the whole, the work on the fifth batch of centralized procurement will be officially launched in most provinces around October
.
The analysis believes that from the background that each round of national procurement and the competition among enterprises is very fierce, the opening of a new round of market competition in the pharmaceutical market has become an inevitable trend.
The market structure of some drugs may be re-divided, and enterprises will also Usher in a new competitive landscape
.
However, it is worth noting that, in the face of the continuous advancement of centralized procurement, a batch of pharmaceutical companies may also be eliminated at an accelerated pace in the future
.
Therefore, the industry has proposed that under the pressure of centralized procurement, pharmaceutical companies need to focus more on the research and development of innovative drugs with relatively high academic content, and strive to launch more innovative products with characteristics in order to remain competitive.
And to compete for more markets
.
China has organized five batches of centralized procurement of drugs.
From the results, a large number of drugs have reduced prices through centralized procurement.
, Especially in the fifth batch of national centralized procurement, the number of varieties and the average decline have reached new highs
.
It is reported that the fifth batch of national procurement of medicines has a total of 61 products selected, with an average decrease of 56%; the varieties involve common diseases such as hypertension, diabetes, coronary heart disease, digestive tract diseases, and drugs for chronic diseases, as well as drugs for major diseases such as lung cancer and pancreatic cancer.
.
In the recent past, many provinces have begun to issue documents clarifying that the fifth batch of national procurement will be implemented
.
In this regard, the industry believes that at the same time that the tide of drug price cuts hits, a new competitive landscape in the pharmaceutical market will also be coming
.
Specifically, starting from October 9th, the results of the fifth batch of national-organized centralized drug procurement will be implemented in Guangdong
.
It is reported that the national centralized procurement set a record high, with a larger scale, more varieties, and a higher proportion of injection varieties
.
For example, the varieties cover common diseases such as high blood pressure, coronary heart disease, diabetes, anti-allergic, anti-infection, gastrointestinal diseases, and chronic disease drugs, as well as drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer
.
It is worth mentioning that there are 16 varieties in this collection that have a decline of more than 90%.
Among them, Jiangsu Hausen's gemcitabine hydrochloride for injection (1g) and other 6 companies have a decline of more than 97%
.
Taking bendamustine hydrochloride (100mg) for injection in the Netherlands as an example of an anti-tumor drug, the cost of each injection has been reduced from 6000 yuan to 786 yuan after the price reduction.
Based on 8 cycles, the patient can save about 160,000 yuan
.
In addition to the sharp price cuts of the selected products this time, Guangdong also linked the prices of non-selected drugs with the same generic names.
For example, more than 10 drugs such as fasudil hydrochloride injection have also dropped significantly, with an average drop of 70%, and the highest drop.
Is 98%
.
Of course, in addition to a large number of drugs in Guangdong Province, which will usher in price cuts, starting from October 10th, Hubei Province will also implement the fifth batch of national drug collection and Chongqing, Hubei, Qiong, Dianqing, Ning, Xinjiang Corps common drug alliance with volume procurement (Hubei ) Results
.
It is understood that the average price of a total of 80 selected drugs will be reduced by more than 50%
.
In fact, in addition to the above-mentioned provinces, Hubei, Henan, Liaoning, Xinjiang, Shanghai, Tibet and other provinces have successively clarified the time for the implementation of the fifth batch of national procurement since August
.
On the whole, the work on the fifth batch of centralized procurement will be officially launched in most provinces around October
.
The analysis believes that from the background that each round of national procurement and the competition among enterprises is very fierce, the opening of a new round of market competition in the pharmaceutical market has become an inevitable trend.
The market structure of some drugs may be re-divided, and enterprises will also Usher in a new competitive landscape
.
However, it is worth noting that, in the face of the continuous advancement of centralized procurement, a batch of pharmaceutical companies may also be eliminated at an accelerated pace in the future
.
Therefore, the industry has proposed that under the pressure of centralized procurement, pharmaceutical companies need to focus more on the research and development of innovative drugs with relatively high academic content, and strive to launch more innovative products with characteristics in order to remain competitive.
And to compete for more markets
.
